Insulin | Page 7 of 16

A Novel Approach to Treating Type 2 Diabetes: Short-Term Intensive Insulin Therapy

Dr. Mariela Glandt, an endocrinologist and director of the Diabetes Medical Center in Tel Aviv uses a short course of intensive insulin therapy in order to "reset" beta cells and help them return to an earlier and more manageable stage of the disease.

Inhaled Insulin for Diabetes: Is Afrezza Worth the Risks?

Will I prescribe Afrezza for people with diabetes? Not a lot, and not for past or present smokers, and not for people with any breathing problems (or heart issues that might cause difficulty breathing), and not without getting pulmonary function testing and explaining all of what I see as potential risks, and not without close follow-up.

The Insulin Games: A Race to Dominate the Growing Market

New long-acting insulin configurations are being developed and launched because the patent on Lantus is set to expire soon. In the United States the Lantus patent expires February 2015 and the drug’s patent expires in Europe in May 2015.

FDA Accepts Sanofi’s NDA for New Basal Insulin, Toujeo

The U.S. Food and Drug Administration (FDA) has accepted for review Sanofi’s New Drug Application (NDA) for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin. The acceptance of the NDA follows the acceptance of the marketing authorization dossier for Toujeo by the European Medicines Agency (EMA) for EU countries on May 27, 2014.

FDA Approves Afrezza Rapid-Acting Inhaled Insulin

The U.S. FDA approved Mannkind Corporation's Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin, to improve glycemic control in adults with diabetes mellitus. Afrezza is administered at the beginning of each meal, or within 20 minutes after starting a meal.

Lilly’s New Basal Insulin Peglispro Proves Equal to Lantus in Phase 3 Clinical Trial

Eli Lilly and Company have announced positive top-line results of three completed Phase III clinical trials in patients with type 2 diabetes for basal insulin peglispro (BIL). Peglispro is being studied as a once-daily treatment for both type 1 and type 2 diabetes. The primary efficacy endpoint of non-inferior reduction in hemoglobin A1c (HbA1c) compared to insulin glargine was met in all three trials.

Smart Insulin: A JDRF Video

In 2003, an MIT chemical engineer founded a company called SmartCells, to develop smart insulin. Smart insulin is a form of insulin that circulates in the bloodstream and turns on when it’s needed to lower blood sugars and off when blood sugars are at safe levels.

FDA Advisory Committee Recommends Approval of Mannkind’s Inhaled Insulin, Afrezza

The U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 1 to recommend that Afrezza (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA

Medtronic Launches the i-port Advance, An All-in-One Injection Port and Inserter

Medtronic has begun distribution of i-port Advance, the first device to combine an injection port and an inserter in one complete set. i-port Advance can be used for people on insulin injection therapy who want to administer insulin conveniently while eliminating the need to puncture the skin with each dose of medication. i-port Advance injection port is FDA approved...

Novo Nordisk Launches NovoFine Plus Ultra-Thin, Ultra-Short Universal Pen Needle

Novo Nordisk has announced the launch of NovoFine Plus, an ultra-thin, ultra-short universal pen needle that aims to make injections more comfortable for patients with diabetes.

Category: Insulin